Although penicillin allergies are reported in 5-15% of the population, over 90% of individuals tested for penicillin allergy are found not to be allergic (1,2). Because true penicillin allergies can be life-threatening, healthcare providers must still use alternative antimicrobials in patients reporting penicillin allergies. Avoidance of β-lactam antibiotics, however, is not without its own risks. Recent data has emerged showing that a penicillin allergy label is associated with higher rates of methicillin-sensitive staphylococcus aureus (MSSA), Clostridium difficile, vancomycin-resistant enterococcus (VRE), increased healthcare utilization, and longer hospital stays (2-4). In one study assessing patients admitted to hospital with haematologic malignancies, a β-lactam allergy label was even associated with increased mortality (4). Certain infections, such as MSSA bacteremia, are associated with higher mortality when treated with a non-β-lactam antibiotic compared with treatment with a β-lactam 5.
The reported “penicillin allergy” is now considered a comorbidity worth investigating. Taking a detailed history and performing penicillin skin testing, when appropriate, is important in assessing individuals reporting a penicillin allergy. Because certain hypersensitivity reactions to medications are life-threatening, patients need to first be screened for contraindications to skin testing and future drug provocation challenges. Studies are currently underway in assessing the impact of large-scale penicillin allergy testing programs.